Literature DB >> 6116757

Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.

S G Al-Dabbagh, J R Idle, R L Smith.   

Abstract

The metabolism of debrisoquine (5 mg kg-1 orally) was investigated in females of 7 strains of rat. Two major metabolic pathways, those of 4- and 6-hydroxylation were found to be polymorphic. The DA strain eliminated in urine only 7-10% of the dose as 4-hydroxy-debrisoquine together with 31-55% debrisoquine while the corresponding values for the Lewis strain were 44-55% and 11-17% respectively. Accordingly, DA and Lewis rats were proposed as models for the human PM (poor metabolizer) and EM (extensive metabolizer) drug oxidation phenotypes. To further test this model, DA and Lewis rats were given phenacetin (200 mg kg-1 orally). This underwent O-de-ethylation to paracetamol (52-55%) and aromatic 2-hydroxylation (7-8%) in Lewis rats. The corresponding findings in DA rats were 35-40% O-de-ethylation and 12-13% 2-hydroxylation. It is suggested that, with respect to both debrisoquine and phenacetin, Lewis and DA inbred rat strains afford a model of oxidative drug metabolism for the human EM and PM phenotypes respectively.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116757     DOI: 10.1111/j.2042-7158.1981.tb13740.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  13 in total

1.  Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats.

Authors:  S Koehn; F J Frey; R F Speck; T Zeugin; T Schaffner; A Zimmermann; B M Frey
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

Review 2.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

4.  Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

Authors:  M Pirovino; U Honegger; O Müller; T Zysset; A Küpfer; M Tinel; D Pessayre
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

5.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Genetic heterogeneity of histamine H2-receptors in the mouse vas deferens.

Authors:  J A Calvete; J L Donegan; R J Hayes; N S Oates; T P Sloan
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

7.  The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Authors:  M I Colado; J L Williams; A R Green
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

8.  Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Authors:  L M Distlerath; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

9.  The metabolism and disposition of D-penicillamine in the DA-strain rat.

Authors:  A E Pilkington; R H Waring
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

10.  Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; A Küpfer; E Steiner; C O Meese
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.